HC Wainwright started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI - Free Report) in a research note released on Wednesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $21.00 target price on the stock. HC Wainwright also issued estimates for Trevi Therapeutics' Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.63) EPS, FY2027 earnings at ($0.75) EPS, FY2028 earnings at $0.57 EPS and FY2029 earnings at $1.66 EPS.
TRVI has been the subject of a number of other research reports. Needham & Company LLC reissued a "buy" rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a report on Tuesday, May 20th. B. Riley reissued a "buy" rating and issued a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. D. Boral Capital reissued a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their price target for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Finally, Oppenheimer upped their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Trevi Therapeutics has an average rating of "Buy" and an average target price of $18.63.
Read Our Latest Report on TRVI
Trevi Therapeutics Trading Up 2.2%
NASDAQ TRVI traded up $0.14 during trading on Wednesday, reaching $6.50. The company's stock had a trading volume of 1,449,006 shares, compared to its average volume of 1,214,694. The firm has a market capitalization of $649.30 million, a price-to-earnings ratio of -14.77 and a beta of 0.62. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.39. The firm has a 50 day moving average price of $6.24 and a 200 day moving average price of $4.83.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. On average, equities analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.
Insider Transactions at Trevi Therapeutics
In related news, CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at $1,403,599.54. This represents a 2.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Farrell Simon sold 81,313 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares of the company's stock, valued at approximately $519,075. The trade was a 51.39% decrease in their position. The disclosure for this sale can be found here. 18.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Trevi Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its stake in Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after purchasing an additional 2,894 shares during the last quarter. Strs Ohio bought a new position in Trevi Therapeutics in the 1st quarter valued at approximately $52,000. Raymond James Financial Inc. bought a new position in Trevi Therapeutics in the 4th quarter valued at approximately $49,000. Squarepoint Ops LLC bought a new position in Trevi Therapeutics in the 4th quarter valued at approximately $58,000. Finally, Diversified Trust Co acquired a new position in Trevi Therapeutics in the 1st quarter valued at approximately $94,000. Institutional investors own 95.76% of the company's stock.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
See Also
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
